Adeno-associated virus (AAV) has proven an effective gene delivery vehicle for the treatment of retinal disease. Ongoing clinical trials using a serotype 2 AAV vector to express RPE65 in the retinal pigment epithelium have proven safe and effective. While many proof-of-concept studies in animal models of retinal disease have suggested that gene transfer to the neural retina will also be effective, a photoreceptor-targeting AAV vector has yet to be used in the clinic, principally because a vector that efficiently but exclusively targets all primate photoreceptors has yet to be demonstrated. Here, we evaluate a serotype 5 AAV vector containing the human rhodopsin kinase (hGRK1) promoter for its ability to target transgene expression to rod and cone photoreceptors when delivered subretinally in a nonhuman primate (NHP). In vivo fluorescent fundus imaging confirmed that AAV5-hGRK1-mediated green fluorescent protein (GFP) expression was restricted to the injection blebs of treated eyes. Optical coherence tomography (OCT) revealed a lack of gross pathology after injection. Neutralizing antibodies against AAV5 were undetectable in post-injection serum samples from subjects receiving uncomplicated subretinal injections (i.e., no hemorrhage). Immunohistochemistry of retinal sections confirmed hGRK1 was active in, and specific for, both rods and cones of NHP retina. Biodistribution studies revealed minimal spread of vector genomes to peripheral tissues. These results suggest that AAV5-hGRK1 is a safe and effective AAV serotype/promoter combination for targeting therapeutic transgene expression protein to rods and cones in a clinical setting.
Get full access to this article
View all access options for this article.
References
1.
AlexanderJ. J.et al.2007. Restoration of cone vision in a mouse model of achromatopsia. Nat. Med., 13:685–687.
2.
AmadoD.et al.2010. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci. Transl. Med., 2:21ra16.
3.
AnandV., ChirmuleN., FershM.et al.2000. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum. Gene Ther., 11:449–457.
4.
AnandV., DuffyB., YangZ.et al.2002. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol. Ther., 5:125–132.
5.
AndersonD. H., SternW. H., FisherS. K.et al.1981. The onset of pigment epithelial proliferation after retinal detachment. Invest Ophthalmol. Vis. Sci., 21:10–16.
6.
AnnearM. J., BartoeJ. T., BarkerS. E.et al.2011. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther., 18:53–61.
7.
AshtariM.et al.2011. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J. Clin. Invest, 121:2160–2168.
8.
AuricchioA., KobingerG., AnandV.et al.2001. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet., 10:3075–3081.
9.
BainbridgeJ. W.et al.2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358:2231–2239.
10.
BarkerS. E.et al.2009. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. J. Gene Med., 11:486–497.
11.
BeltranW. A., BoyeS. L., BoyeS. E.et al.2010. rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters. Gene Ther., 17:1162–1174.
12.
BeltranW. A.et al.2012. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A, 109:2132–2137.
13.
BennettJ.et al.2012. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 4:120ra15.
14.
BoyeS. E.et al.2010. Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One, 5:e11306.
15.
BoyeS. L.et al.2011. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol. Vis. Sci., 52:7098–7108.
16.
CalcedoR., VandenbergheL. H., GaoG.et al.2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis., 199:381–390.
17.
CideciyanA. V.et al.2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A, 105:15112–15117.
18.
CideciyanA. V., SwiderM., AlemanT. S.et al.2012. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol. Vis. Sci., 53:841–852.
19.
CurcioC. A.2001. Photoreceptor topography in ageing and age-related maculopathy. Eye (Lond), 15:376–383.
20.
CurcioC. A., AllenK. A., SloanK. R.et al.1991. Distribution and morphology of human cone photoreceptors stained with anti-blue opsin. J. Comp. Neurol., 12:610–624.
21.
CurcioC. A., MedeirosN. E., MillicanC. L.1996. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol. Vis. Sci., 37:1236–1249.
DryjaT.2001. Retinitis pigmentosa and stationary night blindness. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill: New York.
24.
FisherS. K., LewisG., LinbergK. A.et al.2005. Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog. Retin. Eye Res., 24:395–431.
25.
GorbatyukM. S., KnoxT., LaVailM. M.et al.2010. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl. Acad. Sci. U.S.A, 107:5961–5966.
26.
Goto-OmotoS., HayashiT., GekkaT.et al.2006. Compound heterozygous CNGA3 mutations (R436W, L633P) in a Japanese patient with congenital achromatopsia. Vis. Neurosci., 23:395–402.
27.
HaireS. E., PangJ., BoyeS. L.et al.2006. Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. Invest Ophthalmol. Vis. Sci., 47:3745–3753.
28.
HauswirthW. W.et al.2008. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther., 19:979–990.
29.
IvanovaE., HwangG. S., PanZ. H.et al.2010. Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina. Invest Ophthalmol. Vis. Sci., 51:5288–5296.
30.
JacobsonS. G.et al.2006a. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther., 13:1074–1084.
31.
JacobsonS. G.et al.2006b. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther., 17:845–858.
32.
JacobsonS. G.et al.2012. Gene therapy for leber congenital amaurosis caused by RPE65 mutations. safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol., 130:9–24.
33.
KhaniS. C.et al.2007. AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol. Vis. Sci., 48:3954–3961.
34.
KomaromyA. M.et al.2010. Gene therapy rescues cone function in congenital achromatopsia. Hum. Mol. Genet., 19:2581–2593.
35.
LiQ., MillerR., HanY.et al.2008. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis., 14:1760–1769.
36.
LiW.et al.2009. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol. Vis., 15:267–275.
37.
LiX.et al.2011. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse. a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol. Vis. Sci., 52:7–15.
38.
LoteryA. J.et al.2003. Adeno-associated virus type 5. transduction efficiency and cell-type specificity in the primate retina. Hum. Gene Ther., 14:1663–1671.
39.
MackayD. S.et al.2011. Screening of SPATA7 in patients with Leber congenital amaurosis and severe childhood-onset retinal dystrophy reveals disease-causing mutations. Invest Ophthalmol. Vis. Sci., 52:3032–3038.
40.
MaguireA. M.et al.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
41.
MancusoK., HendricksonA. E., ConnorT. B.Jr.et al.2007. Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina. J. Opt. Soc. Am. A Opt. Image Sci. Vis., 24:1411–1416.
42.
MancusoK., HauswirthW. W., LiQ.et al.2009. Gene therapy for red-green colour blindness in adult primates. Nature, 461:784–787.
43.
MaoH., JamesT.Jr., SchweinA.et al.2011. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum. Gene Ther., 22:567–575.
44.
MinS. H.et al.2005. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol. Ther., 12:644–651.
45.
MussolinoC.et al.2011. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther., 18:637–645.
46.
OkanoK.et al.2012. Retinal cone and rod photoreceptor cells exhibit differential susceptibility to light-induced damage. J. Neurochem., 121:146–156.
47.
OwsleyC., JacksonG. R., CideciyanA. V.et al.2000. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol. Vis. Sci., 41:267–273.
48.
PackerO., HendricksonA. E., CurcioC. A.1989. Photoreceptor topography of the retina in the adult pigtail macaque (Macaca nemestrina)J. Comp Neurol., 288:165–183.
49.
PajusolaK., GruchalaM., JochH.et al.2002. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J. Virol., 76:11530–11540.
50.
PangJ.et al.2010. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther., 17:815–826.
51.
PangJ. J.et al.2008. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest Ophthalmol. Vis. Sci., 49:4278–4283.
52.
PangJ. J.et al.2012a. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS. One, 7:e35250.
53.
PangJ. J.et al.2012b. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS. One, 7:e35250.
54.
PawlykB. S.et al.2010. Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis. Hum. Gene Ther., 21:993–1004.
55.
ProvostN.et al.2005. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther., 11:275–283.
56.
RobsonA. G., EganC. A., LuongA.et al.2004. Comparison of fundus autofluorescence with photopic and scotopic fine-matrix mapping in patients with retinitis pigmentosa and normal visual acuity. Invest Ophthalmol. Vis. Sci., 45:4119–4125.
57.
RobsonA. G., MichaelidesM., LuongA.et al.2008a. Functional correlates of fundus autofluorescence abnormalities in patients with RPGR or RIMS1 mutations causing cone or cone rod dystrophy. Br. J. Ophthalmol., 92:95–102.
58.
RobsonA. G., MichaelidesM., SaihanZ.et al.2008b. Functional characteristics of patients with retinal dystrophy that manifest abnormal parafoveal annuli of high density fundus autofluorescence; a review and update. Doc. Ophthalmol., 116:79–89.
59.
RyalsR. C., BoyeS. L., DinculescuA.et al.2011a. Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol. Vis., 17:1090–1102.
60.
RyalsR. C., BoyeS. L., DinculescuA.et al.2011b. Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol. Vis., 17:1090–1102.
61.
SchollH., ChongN. H., RobsonA. G.et al.2004. Fundus autofluorescence in patients with leber congenital amaurosis. Invest Ophthalmol. Vis. Sci., 45:2747–2752.
62.
SimonelliF.et al.2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 18:643–650.
63.
SnodderlyD. M., AuranJ. D., DeloriF. C.1984a. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol. Vis. Sci., 25:674–685.
64.
SnodderlyD. M., BrownK., DeloriF. C.et al.1984b. The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol. Vis. Sci., 25:660–673.
65.
SongS., Scott-JorgensenM., WangJ.et al.2002. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol. Ther., 6:329–335.
66.
StiegerK.et al.2008. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol. Ther., 16:916–923.
SunX.et al.2010. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther., 17:117–131.
69.
SundaramV., MooreA. T., AliR. R.et al.2012. Retinal dystrophies and gene therapy. Eur. J. Pediatr., 171:757–765.
70.
TanM. H.et al.2009. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum. Mol. Genet., 18:2099–2114.
71.
TimmersA. M., ZhangH., SquitieriA.et al.2001. Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol. Vis., 7:131–137.
VandenbergheL. H., BellP., MaguireA. M.et al.2011. Cone and rod transduction with alternative AAV serotypes in the macula of nonhuman primates. Conference Proceedings. The Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL.
74.
WangY., MackeJ., MerbsS. L.et al.1992. A locus control region adjacent to the human red and green visual pigment genes. Neuron, 9:429–440.
75.
WeissE. R., DucceschiM. H., HornerT. J.et al.2001. Species-specific differences in expression of G-protein-coupled receptor kinase (GRK) 7 and GRK1 in mammalian cone photoreceptor cells: implications for cone cell phototransduction. J. Neurosci., 21:9175–9184.
76.
YangG. S., SchmidtM., YanZ.et al.2002. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J. Virol., 76:7651–7660.
77.
YaoJ., FeathersK. L., KhannaH.et al.2011. XIAP therapy increases survival of transplanted rod precursors in a degenerating host retina. Invest Ophthalmol. Vis. Sci., 52:1567–1572.
ZolotukhinS.2005. Production of recombinant adeno-associated virus vectors. Hum. Gene Ther., 16:551–557.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
